4th ADC Toxicity Summit

As ADC pipelines expand and recent safety setbacks sharpen regulatory scrutiny, the industry's only dedicated forum on antibody-drug conjugate toxicity returns to Boston for its fourth edition.

The 2026 programme: predicting, preventing, and mitigating ADC toxicities

The summit is described as the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across the development continuum. The stated programme pillars are toxicity prediction, translational safety assessment, and dose optimisation strategies, areas the source identifies as direct responses to recent safety setbacks across major ADC programmes.

Where nonclinical and clinical safety teams converge on a shared problem

For R&D and regulatory affairs professionals working on ADC programmes, the summit addresses the specific barriers the source names: clinical success, patient safety, and regulatory approval. The translational safety and dose optimisation focus makes it directly relevant to teams navigating IND-enabling studies and early-phase dose escalation decisions.

Registration is available via the event website; prospective attendees should confirm programme details and availability directly with the organiser, Hanson Wade Conferences Ltd.